USP22 crucial for type III interferon signaling and SARS-CoV-2 infection

NewsGuard 100/100 Score

In a recent study posted to the bioRxiv* pre-print server, a team of researchers demonstrated that ubiquitin-specific peptidase 22 (USP22) is a crucial regulator of basal interferon (IFN) signaling in native human intestinal epithelial cells (hIECs).

Innate immunity components, such as pattern recognition receptors (PRRs) and interferon (IFN) signaling, are closely regulated by deubiquitinating enzymes (DUBs), like USP22, that take over the host ubiquitin machinery. The cyclic GMP-AMP synthase (cGAS)-stimulator of interferon genes protein (STING) is a PPR and a sensor for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection that mediates the secretion of pro-inflammatory cytokines during the infection. Upon activation, STING activates interferon-stimulated genes (ISGs) and IFNs, leading to the initiation of antiviral and inflammatory transcriptional programs. 

Amid the coronavirus disease 2019 (COVID-19) pandemic, it is of utmost relevance to identify host factors that control SARS-CoV-2 infection. Although USP22 has been associated with IFN signaling and ISG expression upon viral infections, the mechanisms underlying USP22 priming of PRRs and IFN signaling in native, uninfected environments remain unknown.

Study: USP22 controls type III interferon signaling and SARS-CoV-2 infection through activation of STING. Image Credit: Juan Gaertner / Shutterstock

Study: USP22 controls type III interferon signaling and SARS-CoV-2 infection through activation of STING. Image Credit: Juan Gaertner / Shutterstock

This news article was a review of a preliminary scientific report that had not undergone peer-review at the time of publication. Since its initial publication, the scientific report has now been peer reviewed and accepted for publication in a Scientific Journal. Links to the preliminary and peer-reviewed reports are available in the Sources section at the bottom of this article. View Sources

About the study

In the present study, researchers studied how the prolonged expression of low basal levels of type I and III IFNs primes host responses against SARS-CoV-2 in hIECs. It is worth noting here that the expression of IFN-specific receptors is restricted by cell type and determines IFN responses.

The researchers performed gene-set enrichment analysis on USP22-regulated genes to investigate if gene ontology (GO) sets specifically regulate USP22. They used quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR) to validate the USP22-regulated changes in gene expression.

Wild-type (WT), non-human target cells (NHT) CRISPR/Cas9 control Caco-2 cells and USP22 knockout (KO) Caco-2 cells were subjected to infection with SARS-CoV-2 particles at a multiplicity of infection (MOI) of 1 to test the functional relevance of the increased antiviral signaling upon loss of USP22 expression. Infected Caco-2 cells, fixed at 24 hours post-infection (hpi), were subjected to quantification of SARS-CoV-2 replication via immunofluorescence to recognize SARS-CoV-2 nucleocapsid protein.

Profiling USP22-mediated gene expression in HT-29 hIECs. A. Volcano plot showing the differential gene expression patterns of two independent single-cell HT-29 USP22 CRISPR/Cas9 KO clones (#16 and #62) compared to CRISPR/Cas9 control (NHT) HT-29 cells. Color code represents the log2 foldchange compared to NHT. B. Heatmap of the top-50 differentially regulated genes between HT-29 USP22 KO single clones #16 and #62 and the NHT control. Color coding represents the row-wise scaled (Z-score) RNA intensities. Genes are sorted according to their log2 fold change, compared to NHT. C. Basal mRNA expression levels of the indicated genes were determined in control and two independent USP22 KO HT-29 single clones using qRT-PCR. Gene expression was normalized against 28S mRNA and is presented as x-fold mRNA expression compared to NHT. Mean and SD of three independent experiments in triplicate are shown. *P < 0.05; **P < 0.01, ***P < 0.001.

Profiling USP22-mediated gene expression in HT-29 hIECs. A. Volcano plot showing the differential gene expression patterns of two independent single-cell HT-29 USP22 CRISPR/Cas9 KO clones (#16 and #62) compared to CRISPR/Cas9 control (NHT) HT-29 cells. Color code represents the log2 foldchange compared to NHT. B. Heatmap of the top-50 differentially regulated genes between HT-29 USP22 KO single clones #16 and #62 and the NHT control. Color coding represents the row-wise scaled (Z-score) RNA intensities. Genes are sorted according to their log2 fold change, compared to NHT. C. Basal mRNA expression levels of the indicated genes were determined in control and two independent USP22 KO HT-29 single clones using qRT-PCR. Gene expression was normalized against 28S mRNA and is presented as x-fold mRNA expression compared to NHT. Mean and SD of three independent experiments in triplicate are shown. *P < 0.05; **P < 0.01, ***P < 0.001.

Study findings

USP22-mediated gene expression profiling in hIECs (cell line HT-29) identified transcriptional and extranuclear targets for USP22. The quantification of alterations in gene expression in two independent HT-29 USP22 KO single-cell clones revealed a marked alteration in gene expression, with 401 genes up-regulated and 182 down-regulated.

The differential regulation of gene expression, as well as loss of USP22 expression, was also demonstrated by qRT-PCR of the USP22-dependent up and down-regulated genes, confirming the quality of the microarray.

GO analysis revealed an enrichment of genes linked to type I and II IFN signaling. Compared to control NHT HT-29 cells, in KO HT-29 cells, USP22 regulated viral genome replication and several other viral processes, such as the IFN-γ, and IFN-γ mediated signaling pathways. The GO terms of strongly downregulated genes were enriched in mitochondrial translation and gene expression. In addition, the GO analysis showed processing of transfer ribonucleic acid (tRNA), ribosomal RNA (rRNA), and non-coding RNA (ncRNA).

qRT-PCR confirmed that the expression of several ISGs increased in two independent HT-29 USP22 KO clones, including BST2, PARP9, USP18, OAS3, IFIT1, IRF9, ISG15, OAS2, IFI27, and IFI6. In addition, loss of USP22 increased protein expression of MX1, IRF9, ISG56, and ISG20, suggesting that USP22 controls the expression of IFN signaling and viral defense genes, even in the absence of exogenous IFN stimulation or virus infection.

The immunofluorescence results showed that USP22-deficient cells displayed a substantial decrease in SARS-CoV-2 infection compared to infected control cells. Notably, USP22-deficient Caco-2 cells also expressed higher levels of IFN-λ1, compared to control cells, whereas their IFN-α and IFN-β expression remained unaltered. Together, these findings indicated that USP22 controls SARS-CoV-2 infection, replication, and the generation of de novo infectious SARS-CoV-2 particles, partially through STING, a mediator of IFN-λ1 production in HT-29 cells.

Conclusions 

Cellular functions of USP22 in viral infections, interferon signaling, USP22 interactions, and USP22-mediated ubiquitination have been studied previously. According to the authors, the current study is the first study to depict the basal functions of USP22 in the regulation of ISG expression and STAT signaling in native hIECs.

These findings have important implications for SARS-CoV-2 infections. They identified USP22 as a negative regulator of type III IFN secretion in basal settings in the absence of exogenous IFNs or viral infection. In addition, it revealed that USP22 regulated both basal and 2’3’-cGAMP induced STING ubiquitination and activation. However, it remains undetermined why USP22 alters a significant fraction of IFN-unrelated genes while the expression of other genes is not altered upon the loss of USP22 expression. 

This news article was a review of a preliminary scientific report that had not undergone peer-review at the time of publication. Since its initial publication, the scientific report has now been peer reviewed and accepted for publication in a Scientific Journal. Links to the preliminary and peer-reviewed reports are available in the Sources section at the bottom of this article. View Sources

Journal references:

Article Revisions

  • May 11 2023 - The preprint preliminary research paper that this article was based upon was accepted for publication in a peer-reviewed Scientific Journal. This article was edited accordingly to include a link to the final peer-reviewed paper, now shown in the sources section.
Neha Mathur

Written by

Neha Mathur

Neha is a digital marketing professional based in Gurugram, India. She has a Master’s degree from the University of Rajasthan with a specialization in Biotechnology in 2008. She has experience in pre-clinical research as part of her research project in The Department of Toxicology at the prestigious Central Drug Research Institute (CDRI), Lucknow, India. She also holds a certification in C++ programming.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Mathur, Neha. (2023, May 11). USP22 crucial for type III interferon signaling and SARS-CoV-2 infection. News-Medical. Retrieved on April 16, 2024 from https://www.news-medical.net/news/20220207/USP22-crucial-for-type-III-interferon-signaling-and-SARS-CoV-2-infection.aspx.

  • MLA

    Mathur, Neha. "USP22 crucial for type III interferon signaling and SARS-CoV-2 infection". News-Medical. 16 April 2024. <https://www.news-medical.net/news/20220207/USP22-crucial-for-type-III-interferon-signaling-and-SARS-CoV-2-infection.aspx>.

  • Chicago

    Mathur, Neha. "USP22 crucial for type III interferon signaling and SARS-CoV-2 infection". News-Medical. https://www.news-medical.net/news/20220207/USP22-crucial-for-type-III-interferon-signaling-and-SARS-CoV-2-infection.aspx. (accessed April 16, 2024).

  • Harvard

    Mathur, Neha. 2023. USP22 crucial for type III interferon signaling and SARS-CoV-2 infection. News-Medical, viewed 16 April 2024, https://www.news-medical.net/news/20220207/USP22-crucial-for-type-III-interferon-signaling-and-SARS-CoV-2-infection.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
COVID-19 shatters decades of global health progress, slashing life expectancy